SWEDISH ORPHAN BIOVITRUM

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2010-01-01

Employees: -

Market Cap: $10.7B

Website: http://www.sobi.com/

Clinical Trials

A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients

Phase 4

Active, not recruiting

Conditions: Primary Hemophagocytic Lymphohistiocytosis

Interventions: Drug: Emapalumab-Lzsg 5 MG/ML [Gamifant]

First Posted Date: 2023-02-24

Last Posted Date: 2024-10-15

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 13

Registration Number: NCT05744063

Locations: 🇨🇳
Swedish Orphan Biovitrum Research site, Zhengzhou, China

Evaluate the PK Efficacy Safety and Tolerability of Pegcetacoplan in Patients With Thrombotic Microangiopathy

Phase 2

Completed

Conditions: Transplant-Associated Thrombotic Microangiopathy

Interventions: Drug: Pegcetacoplan

First Posted Date: 2021-12-08

Last Posted Date: 2024-12-19

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 12

Registration Number: NCT05148299

Locations: 🇬🇷
University General Hospital "Attikon", Athens, Chaidari, Greece
🇫🇷
CHU de Saint-Etienne, Saint-Priest-en-Jarez, France
🇬🇷
General Hospital of Thessaloniki "G. Papanikolaou", Hematology Department - BMT Unit, Thessaloníki, Greece

and more 11 locations

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)

Phase 3

Suspended

Conditions: Cold Agglutinin Disease

Interventions: Drug: Pegcetacoplan

First Posted Date: 2021-10-27

Last Posted Date: 2024-04-11

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 57

Registration Number: NCT05096403

Locations: 🇬🇪
Ltd M. Zodelava Hematology Centre, Tbilisi, Georgia
🇬🇧
Churchill Hospital, Oxford, United Kingdom
🇧🇪
CHU de Liège, Liège, Belgium

and more 41 locations

Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

Phase 3

Active, not recruiting

Conditions: Macrophage Activation Syndrome
SJIA
MAS
Secondary Hemophagocytic Lymphohistiocytosis
Still Disease
Systemic Lupus Erythematosus
AOSD

Interventions: Drug: Emapalumab

First Posted Date: 2021-08-12

Last Posted Date: 2024-10-15

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 41

Registration Number: NCT05001737

Locations: 🇧🇪
Universitair Ziekenhuis Leuven, Leuven, Belgium
🇨🇳
Children's Hospital of Fudan University, Shanghai, China
🇳🇱
UMC Utrecht, Utrecht, Netherlands

and more 43 locations

An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP

Active, not recruiting

Conditions: Immune Thrombocytopenia
ITP

Interventions: Drug: Avatrombopag

First Posted Date: 2021-06-29

Last Posted Date: 2024-10-03

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 150

Registration Number: NCT04943042

Locations: 🇨🇭
Swedish Orphan Biovitrum Research Site 802, Basel, Switzerland
🇪🇸
Swedish Orphan Biovitrum Research Site 606, Oviedo, Spain
🇩🇪
Swedish Orphan Biovitrum Research Site 103, Bad Homburg, Germany

and more 52 locations

A Study to Evaluate Emapalumab in Japanese Healthy Volunteers.

Phase 1

Completed

Conditions: Rare Diseases

Interventions: Drug: NI-0501
Drug: Saline

First Posted Date: 2021-02-21

Last Posted Date: 2023-11-30

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 8

Registration Number: NCT04765553

Locations: 🇯🇵
P-One Clinic, Tokyo, Japan

Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST)

Completed

Conditions: Hemophilia B
Hemophilia A

First Posted Date: 2021-02-01

Last Posted Date: 2022-08-31

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 180

Registration Number: NCT04731701

Locations: 🇫🇷
Swedish Orphan Biovitrum Clinical site, Toulouse, France

Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.

Phase 2

Terminated

Conditions: Graft Failure

Interventions: Drug: Emapalumab

First Posted Date: 2021-01-29

Last Posted Date: 2023-12-28

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 2

Registration Number: NCT04731298

Locations: 🇨🇦
CHU Sainte-Justine, Montréal, Quebec, Canada
🇮🇱
The Rambam Academic Hospital, Haifa, Israel
🇮🇱
Hadassah Hebrew University, Jerusalem, Israel

and more 2 locations

A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II

Phase 3

Completed

Conditions: Chronic Gout

Interventions: Drug: SEL-212 high-dose
Other: Placebo
Drug: SEL-212 low-dose

First Posted Date: 2020-10-22

Last Posted Date: 2024-02-20

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 153

Registration Number: NCT04596540

Locations: 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸
Arthritis Center of North Georgia, LLC, Gainesville, Georgia, United States
🇺🇸
Carolina Research Center, Inc, Shelby, North Carolina, United States

and more 50 locations

A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy

Phase 3

Completed

Conditions: Chronic Gout

Interventions: Other: Normal Saline
Drug: SEL-212 low-dose
Drug: SEL-212 high-dose

First Posted Date: 2020-08-14

Last Posted Date: 2024-02-20

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 112

Registration Number: NCT04513366

Locations: 🇺🇸
Clinical Research Of West Florida Incorporated, Clearwater, Florida, United States
🇺🇸
Clinical Pharmacology Study Group, Worcester, Massachusetts, United States
🇺🇸
Klein and Associates, M.D., P.A., Hagerstown, Maryland, United States

and more 36 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy